article thumbnail

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel

Fierce Pharma

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 275
article thumbnail

Europe names hundreds of critical medicines in quest to counter drug shortages

Fierce Pharma

Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S.

Medicine 357
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mitigating medicines shortages in Europe

European Pharmaceutical Review

While unsolicited and burdensome, medicine shortages are an obstacle faced by the pharmaceutical industry. In 2023, a combination of factors, including increased demand (particularly for critical medicines), economic inflation, as well as international geopolitical unrest, has led to Europe’s supply chain being acutely affected.

Medicine 101
article thumbnail

Europe publishes first list of critical medicines

European Pharmaceutical Review

The European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the first Union list of critical medicines. The Union list was put together following a review of 600 active substances taken from six national lists of critical medicines.

Medicine 100
article thumbnail

NICE recommends first medicine for severe alopecia areata

European Pharmaceutical Review

I am delighted that we are now able to recommend this innovative treatment… [because it is] the first time a medicine for severe alopecia areata has been recommended by NICE for use in the NHS,” Helen Knight, Director of Medicines Evaluation at NICE noted. NICE’s decision was published in its Final Draft Guidance.

article thumbnail

Prime Medicine joins the biotech IPO queue, seeking $140m

pharmaphorum

Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25

article thumbnail

The future of medicines information: A leap forward is now on the horizon

Fierce Pharma

Written by: Philippe Michiels, Principal Architect at Datapharm | Datapharm presents the case for standardizing digital formats of medicines information, which for too long has been characterized by unstructured data.

Medicine 130